Table 1. Baseline patient characteristicsa.
| Patient (n = 203) | |
|---|---|
| Age (year) | 58 (40–84) |
| Sex, Male / Female | 164 / 39 |
| Etiology, HBV / HCV / Alcohol / Others | 142 / 17 / 22 / 22 |
| Ascite, None / Present | 172 / 31 |
| Portal hypertension, None / Present | 155 / 48 |
| ECOG, 0 / 1 / 2 / 3 b | 115 / 49 / 27 / 4 |
| Child Pugh Class, A / B / C b | 141 / 49 / 5 |
| Tumor Maximum Size (cm) | 5.7 (0.8–28) |
| Tumor number, single / multiple | 102 / 101 |
| Metastasis, None / present | 169 / 34 |
| Treatment | |
| TAC / +PEI / +Radiation / Sorafenib / Others | 127 / 3 / 16 / 5 / 52 |
| Laboratory data, median (range) | |
| Platelet (x109/L) | 131 (0.95–502) |
| Prothrombin time (INR) | 1.22 (0.98–2.46) |
| Bilirubin (mg/dL) | 1.2 (0.3–9.7) |
| AST (U/L) | 51.5 (11–522) |
| ALT (U/L) | 36 (11–392) |
| Albumin (d/dL) | 3.6 (0.8–5.1) |
| Creatinine (mg/dL) | 0.7 (0.4–1.3) |
| Sodium (mmol/L) | 138 (125–144) |
| AFP (ng/mL) | 57.6 (1.3–3,000) |
| PIVKA-II (mAU) | 193 (10–75000) |
HBV, hepatitis B virus; HCV, hepatitis C virus; TAC, transarterial chemotherapy; PEI, percutaneous ethanol infection; AST, aspartate aminotransferase; ALT, alanine aminotransferase; AFP, alpha fetoprotein; PIVKA-II, protein induced by vitamin K absence or antagonist II.
aThe continuous variables are presentedas median (range).
bFor ECOG (Eastern Cooperative Oncology Group) and Child Pugh classification, 8 patients had no data.